Sara Napoli

8PUBLICATIONS
63CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 03, 2026
Aberrant expression of HERV-K envelope in lymphoma represents an opportunity for novel treatments.

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Oct 07, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas, Sara Napoli, Eugenio Gaudio

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

|Nov 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.

Alberto J Arribas, Eugenio Gaudio, Sara Napoli

|Apr 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance.

Zoë Johnson, Chiara Tarantelli, Elisa Civanelli

Pageof 2

Frequent Collaborators

8 joint publications

Luciano Cascione

8 joint publications

Francesco Bertoni

7 joint publications

Chiara Tarantelli

6 joint publications

Alberto J Arribas